Drug information
- Brand Name: Aclasta
- Active ingredient: One 100 ml bottle of solution contains 5 mg of zoledronic acid (anhydrous).
- Excipients: Mannitol, sodium citrate, water for injection.
- Dosage form: Solution for infusion. The solution is sterile, transparent and colorless.
- Manufacturer: Novartis.
- Aclasta drug quote : Contact directly or leave a comment https://thuoclp.com/chatFB type “ Aclasta”.
Drug Aclasta 5mg/100ml What is zoledronic acid?
Aclasta contains the active ingredient zoledronic acid (also known as zoledronate). The drug belongs to the group of drugs called bisphosphonates. Zoledronic acid is thought to inhibit the release of calcium from bone. It is used to treat Paget's disease and osteoporosis in postmenopausal women.
The active ingredient zoledronic acid belongs to the group of nitrogenous bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption.
What does Aclasta do?
- Treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral, and nonvertebral fractures and to increase bone mineral density.
- Prevention of clinical fractures after hip fractures in men and women.
- Treatment of Paget's disease of bone.
Who should not take Aclasta?
- Hypersensitivity to the active substance Zoledronic acid or to any of the excipients or to any bisphosphonate.
- Low blood calcium.
- Pregnant and lactating women.
Dosage and how to use Aclasta?
Dosage
Dosage for adults
- Treatment of Postmenopausal Osteoporosis: For the treatment of postmenopausal osteoporosis, the recommended dose is a single intravenous infusion of 5 mg once a year.
- Prevention of clinical fracture after hip fracture: For the prevention of clinical fracture following hip fracture, the recommended dose is a single intravenous infusion of 5 mg once a year.
- Treatment of Paget's disease of bone: For the treatment of Paget's disease, Aclasta should only be prescribed by physicians experienced in the treatment of Paget's disease of bone. The recommended dose is a single intravenous infusion of 5 mg.
Dosage for children: Aclasta is not recommended for children and adolescents under 18 years of age.
Other dosage
- Patients with Renal Impairment: Aclasta is not recommended for patients with creatinine clearance <35mL/min to ensure an adequate level of safety against renal impairment in patients receiving the drug. No dose adjustment is required in patients with creatinine clearance >35 ml/min.
- Patients with hepatic impairment: No dose adjustment is required.
- Elderly (≥ 65 years): No dose adjustment is necessary because bioavailability, distribution and elimination are similar in elderly and young patients.
How to use the drug?
Aclasta (5mg/100ml available in infusion solution) is given intravenously; transmission time should not be less than 15 minutes. Calcium and vitamin D should be supplemented before and after the infusion.
see more at:
https://nhathuoconline.org/thuoc-dieu-tri/thuoc-loang-xuong/thuoc-aclasta-5mg/
https://thuoclpvietnamese.business.site/posts/5182882392586860587
https://twitter.com/thuoclp/status/1406882559057825794
https://www.pinterest.com/pin/721279696564887903/
https://issuu.com/thuoclp/docs/thuoclp-aclasta-5mg100ml-gia-thuoc-aclasta-loang-x
https://www.vietnamta.vn/thuoclp/?link-id=113434
https://linkhay.com/blog/74129/thuoc-aclasta-5mg-100ml-la-thuoc-gi-a-thuoclp
Nhận xét
Đăng nhận xét